Novo Nordisk and University of Oxford to ally on diabetes research

Novo Nordisk has announced a new collaboration with the University of Oxford that aims to develop new approaches to treating type 2 diabetes.

Scientists from both organisations will come together to develop innovative approaches for treating the disease, while Novo Nordisk will also invest in a new research centre on the premises of the University of Oxford.

Dubbed the Novo Nordisk Research Centre Oxford, the site will employ up to 100 Novo Nordisk researchers, based in an Oxford University research centre. The company will spend 115 million pounds supporting the facility over a period of ten years.

It will focus on innovation within early-stage research that has potential to substantially impact the future treatment of type 2 diabetes and its complications, encouraging cross-fertilisation of ideas between academic researchers from the two organisations.

Mads Krogsgaard Thomsen, chief science officer and executive vice-president of Novo Nordisk, said: "Our vision is that the unique combination of industrial and academic know-how will eventually lead to a new generation of treatments to improve the lives of people with type 2 diabetes."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.